Core Viewpoint - The potential litigation risks surrounding Kenvue Inc. due to President Trump's comments on Tylenol's link to autism have led to a significant decline in the company's stock price, raising investor concerns about the future of the company [1][2][3]. Company Overview - Kenvue Inc., which was spun off from Johnson & Johnson in 2023, is facing scrutiny over its flagship product, Tylenol, amid allegations that its use during pregnancy may increase autism risk [5]. - The company has a diversified portfolio, including brands like Listerine, Band-Aid, and Bengay, but Tylenol remains a critical product for its revenue [5]. Market Reaction - Kenvue's stock fell by 7.47% to $16.97 per share on Tuesday, with a year-to-date decline of 20.25% and a 26.28% drop over the year [6]. - The stock's performance is characterized by a weaker price trend across short, medium, and long-term evaluations, indicating potential challenges ahead [6]. Legal and Scientific Response - In light of the controversy, Kenvue has issued a statement on its website asserting that credible scientific data does not support a link between acetaminophen and autism, indicating the company's readiness to address both scientific claims and potential lawsuits [4][5].

Market Overview - U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average up 0.14% to 46,381.54, the S&P 500 increasing by 0.4% to 6,693.75, and the Nasdaq rising 0.7% to 22,788.98 [1] Nvidia Corp. (NVDA) - Nvidia shares rose 3.97% to close at $183.61, reaching an intraday high of $184.55 and a low of $174.71, with a 52-week range of $86.63 to $184.55 [1] - The company announced a significant $100 billion investment to enhance OpenAI's next-gen AI infrastructure, deploying Nvidia-powered systems to support this initiative [1] Kenvue Inc. (KVUE) - Kenvue's stock dropped 7.47% to close at $16.97, with a high of $17.96 and a low of $16.89, and a 52-week range of $16.89 to $25.17 [2] - The stock spiked 4.4% in after-hours trading to $17.72, following news of a potential announcement from the Trump administration regarding health concerns over acetaminophen in Tylenol, which could impact Kenvue's product sales [2] Rivian Automotive Inc. (RIVN) - Rivian's stock surged 5.98% to $15.24, with an intraday high of $15.43 and a low of $14.11, and a 52-week range of $9.50 to $17.14 [3] - The company held a kickoff ceremony for its new Georgia plant, expected to create thousands of jobs and support its global expansion [3] MicroCloud Hologram Inc. (HOLO) - MicroCloud Hologram saw a 6.72% increase, closing at $5.56, with a high of $5.68 and a low of $4.90, and a 52-week range of $4.16 to $375.20 [4] - In after-hours trading, the stock shot up over 22% to $6.80, following the proposal of an innovative solution for controlling quantum photonic states, which could have significant applications in quantum optics [4] Opendoor Technologies Inc. (OPEN) - Opendoor's shares fell 12.43% to $8.38, with a high of $9.45 and a low of $8.32, and a 52-week range of $0.51 to $10.87 [5] - In after-hours trading, the stock fell by 5.7% to $7.90, following a rally sparked by hedge fund manager Eric Jackson's announcement of a position in Better Home & Finance, leading to a shift in investor focus [5] Stock Rankings - Benzinga's Edge Stock Rankings indicate Nvidia stock has a Value in the 4th percentile but Momentum in the 86th percentile [6]

Group 1 - The Trump administration has issued warnings regarding the risks associated with the use of a specific product during pregnancy, which the company disputes [1]

Kenvue shares fell over 7% to a record low during Monday's session ahead of an announcement at the White House. The stock climbed in after-hours trading. Tylenol maker Kenvue said that scientific studies showed that there was no link between acetaminophen and autism. Justin Sullivan / Getty Images Close KEY TAKEAWAYS Shares of Tylenol maker Kenvue (KVUE) dropped Monday ahead of an anticipated report by the Trump administration linking pregnant women's use of the painkiller to autism. Investopedia requires w ...

For more, let's bring in Dr.. Ashish Jaw, uh, dean of Brown University School of Public Health and former White House COVID response coordinator during the Biden administration. Dr.. Jaw, great to have you with us. This physician's notice uh, on acetaminophen for use during pregnancy. It doesn't seem as stringent as perhaps the markets had expected because it says that basically it allows doctors or doesn't allow, but it says you can still take it um, but you should limit it. Um, is that not as as bad as yo ...

Kenvue Inc.美股盘后涨超4%。 来源：滚动播报 ...

The Trump administration said acetaminophen could cause autism. Doctors maintain it is safe during pregnancy. ...

Core Insights - Nvidia's investment of up to $100 million in OpenAI has boosted optimism in the artificial intelligence sector, contributing to record highs in major U.S. equity indexes [3][7] - Teradyne's shares surged 13% following a price target increase by Susquehanna Financial, driven by strong demand trends and partnerships with Taiwan Semiconductor Manufacturing Company [4][8] - Oracle's shares rose 6.3% after being confirmed as part of a consortium to control TikTok's U.S. operations, alongside leadership changes within the company [5] - Moderna's shares increased by 5.2% after the CDC's vaccine panel updated its recommendations regarding COVID vaccinations [6] - Kenvue's shares dropped 7.5% due to reports linking Tylenol use during pregnancy to autism, despite the company asserting no scientific link [10] - Westinghouse Air Brake Technologies (WAB) shares rose 4.9% following a $4 billion deal to supply locomotives to Kazakhstan's national railway [9] Company-Specific Developments - Nvidia's stock rose 4% as it announced plans to invest significantly in AI, reflecting a broader trend of tech stocks performing well [3] - Teradyne's strong performance is attributed to its role in semiconductor testing and partnerships with major industry players [4] - Oracle's leadership transition to co-CEOs and its involvement with TikTok has positively impacted its stock performance [5] - Moderna's stock gain is linked to the CDC's revised guidance on COVID vaccinations, indicating a potential shift in public health policy [6] - Kenvue's stock decline highlights the impact of regulatory announcements on consumer health companies [10] - WAB's contract for locomotives indicates a positive outlook for the rail equipment sector amid increasing infrastructure investments [9]

Core Viewpoint - The Trump administration has drawn an unproven link between acetaminophen use during pregnancy and autism, contradicting existing scientific literature that suggests no causal relationship [1][4][9] Group 1: Acetaminophen and Pregnancy - Acetaminophen, particularly in the form of Kenvue's Tylenol, is widely regarded as a safe option for pain and fever relief during pregnancy when used at recommended doses [2] - Kenvue has expressed strong disagreement with the administration's claims, emphasizing that independent scientific evidence supports the safety of acetaminophen and warns against the health risks posed to expecting mothers if they avoid the drug [3][4] Group 2: Risks of Untreated Conditions - Untreated fever and pain during pregnancy can lead to serious risks for both the mother and infant, including miscarriage, birth defects, and high blood pressure, as noted by the Society for Maternal-Fetal Medicine [4] Group 3: Leucovorin as a Treatment - The Trump administration has also highlighted leucovorin as a potential treatment for autism symptoms, with some early clinical trials indicating its effectiveness in improving symptoms in children with autism spectrum disorder [5] - The FDA announced approval for a version of leucovorin previously made by GSK, although there was a subsequent request to withdraw this notice [6] Group 4: Broader Context of Autism Research - Robert F. Kennedy Jr. has focused on autism within the Health and Human Services department, pledging to identify its causes and eliminate exposures, while also launching extensive research efforts involving numerous scientists [8] - The scientific consensus suggests that autism arises from a complex interplay of genetic and environmental factors, making it improbable that a single cause accounts for the rising rates of the disorder [9]

Core Viewpoint - Kenvue Inc. (KVUE), the parent company of Tylenol, is experiencing a decline in stock price due to concerns raised by the Trump administration linking Tylenol to autism risk, despite existing studies refuting this claim [2][5][6]. Company Overview - Kenvue was spun off from Johnson & Johnson in 2023 and is known for various household products, including Tylenol, Band-Aid, Listerine, and Zyrtec [3]. - Tylenol, containing acetaminophen, has been available over-the-counter in the U.S. since 1960 and is widely used for pain relief and fever reduction [4]. Industry Concerns - Federal health officials are expected to announce concerns regarding the use of acetaminophen by pregnant women, citing research suggesting a potential link to autism [5]. - The CDC reported that the diagnosis rate of autism in American 8-year-olds has increased from one in 150 in 2000 to one in 31 in 2022, highlighting a growing public health concern [8]. Response from Kenvue - Kenvue has stated that acetaminophen does not cause autism, aiming to clarify the safety of their product amidst rising concerns [8].